Volume 86 Issue 50 | p. 17 | Concentrates
Issue Date: December 15, 2008

Two Advances On The Malaria Front

Department: Business

Pfizer and the Italian pharmaceutical company Sigma-Tau Industrie Farmaceutiche Riunite will market the antimalaria drug Eurartesim in Africa. Now in Phase III clinical studies, the therapy is a fixed-dose combination of dihydroartemisinin and piperaquine that was developed jointly by the nonprofit Medicines for Malaria Venture and Sigma-Tau. Separately, GlaxoSmithKline's RTS, S/AS vaccine continues to show promise in Phase II clinical trials by protecting a significant proportion of infants and young children . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society